IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy
JG Krueger, K Eyerich, VK Kuchroo… - Frontiers in …, 2024 - frontiersin.org
Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory
cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis …
cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis …
Guselkumab in Crohn's disease: the IL-23 race continues
M Fumery, A Buisson - The Lancet Gastroenterology & Hepatology, 2024 - thelancet.com
TNF antagonists, anti-integrin antibodies, and antibodies against IL-12 and IL-23 are the
main therapeutic options in Crohn's disease. 1 Upadacitinib, an oral, small-molecule JAK …
main therapeutic options in Crohn's disease. 1 Upadacitinib, an oral, small-molecule JAK …
Neue Immunsuppressiva und das Risiko opportunistischer Infektionen
F Reinhardt, A von Braun, H Trawinski - Arthritis und Rheuma, 2024 - thieme-connect.com
Die neuen therapeutischen Immunmodulatoren haben aufgrund ihres Wirkmechanismus
unterschiedliche Infektionsrisiken. IL-1-Blockade erhöht vor allem das Risiko für bakterielle …
unterschiedliche Infektionsrisiken. IL-1-Blockade erhöht vor allem das Risiko für bakterielle …